The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. ...
Source:
American Association for Cancer Research
Sunday, November 8, 2009